Involvement of MAPK phosphatase-1 in dexamethasone-induced chemoresistance in lung cancer

Journal of Chemotherapy

Volumn 23, Issue 4, 2011, Pages 221-226

  Huang, Jian ^a   Wang, Haibo ^a   Song, Zhuqin ^b   Lin, Xueping ^b   Zhang, Chengwen ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JIAXING UNIVERSITY   (China)

Author keywords

Chemotherapy resistance; DEX; MKP 1

Indexed keywords

CISPLATIN; DEXAMETHASONE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SYNAPTOPHYSIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER TISSUE; CELL SURVIVAL; CELL VIABILITY; CHEMORESISTANCE; CHINESE; CLINICAL ARTICLE; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE SECTION; UPREGULATION;

EID: 80052749283     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.4.221     Document Type: Article

References (35)

1. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Can cer 2004; 110: 155-169.
2. Office for National Statistics Living in Britain: Preliminary Results from the 1996 General Household Survey. Office for National Statistics. The Stationery Office: London, 1997.
3. Cancer Research UK: Statistics and Prognosis for Lung Cancer. Cancer Research UK, 2004.
4. Gassier N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM et al. Dexmethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 2005; 92: 1084-1088.
5. Cheng L, Du C, Murray D, Tong X, Zhang YA, Chen BP et al. A GFP reporter system to assess gene transfer and expression in human hematopotietic progenitor cells. Gene Ther 1997; 4(10): 1013-1022.
6. Aapro MS. Present role of corticosteroids as antiemetics. In Recent Results in Cancer Research Volume 121. Springer Verlag, Berlin, 1991.
7. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332(1): 1-5.
8. The Italian Group for Antiemetic Research: Dexmethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342(21):1554-1559.
9. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R et al. Dexmethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18: 1960-1966.
10. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumors: implications for effectiveness of cytotoxic treatment and metas tases. Lancet Oncology 2006; 7: 425-430.
11. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol 2003; 178: 5-12.
12. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Corzen SD. Glu cocorticoid Receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276: 16649-16654.
13. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64: 1757-1764.
14. Zhang C, Marme A, Wenger T, Gutwein P, Edler L, Rittgen W et al. Glucocorticoid-mediated inhibiton of chemotherapy in ovarian carcinomas. Int J Oncol 2006; 2: 551-557.
15. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), and immediately early gene product, is a dual specificity phosphatase that dephos-phorylates MAP kinase in vivo. Cell 1993; 75: 487-493.
16. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W et al. Expression of mitogen activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J pathol 1996;149:1553-1564.
17. Wu JJ, Bennett AM. Essential Role for mitogen-activated protein (MAP) Kinase Phosphatase-1 in Stress-responsive MAP Kinase and Cell Sur vival Signaling. J Biol Chem 2005; 280(16): 16461-16466.
18. Wu W, Pew T, Pang D, Zou M, Conzen SD. Glucocorticoid receptor- induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-asso- ciated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280(6): 4117-24.
19. Franklin CC, Srikanth S, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 1997; 272: 16917-16923.
20. Dorr RT, Von Hoff DD. Drug monographs, cisplatin, in: R.T.Dorr, D.D.Von Hoff (Eds.), Cancer Chemotherapy Handbook, Appleton & Lange, Norwalk, 1994: 286-298.
21. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the mole-vular level. Oncol Rep 2003; 10: 1663-1682.
22. Losa JH, Psrada Cobo C, Viniefra JG, Sanchez-Arevalo Lobo VJ, Ramon Cajal S, Sanchez-Prieto R, et al. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogen 2003; 22: 3998-4006.
23. Zhang QX, Feng R, Zhang W, Ding Y, Yang JY, Liu GH. Role of stress-activated MAP kinase p38 in cisplatin- and DTT-induced apoptosis of the esophageal carcinoma cell line Ecal09. World J Gastroenterol 2005; 11: 4451-4456.
24. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Bio Rev 2008; 68:320-344.
25. Wada T, Penninger JM. Mitogen-activated protein kinases in apopto sis regulation Oncogene 2004; 23: 2838-2849.
26. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-3422.
27. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT. The pharmacokinetics of single high doses of dexamethasone in cancer pa tients. Eur J Clin Pharmacol 1987; 32: 593-596.
28. Morisco C, Marrone C, Trimarco V, Crispo S, Monti MG, Sadoshima J et al. Insulin resistance affects the cytoprotective effect of insulin in car- diomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res 2007; 76(3): 453-464.
29. Vangipuram SD, Wang ZJ, Lyman WD. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer 2010; 54(3): 361-368.
30. Laderoute KR, Mendonca HL, Cataoagan JM, Knapp AM, Giaccia AJ, Stork PJ et al. Mitogen-activated protein kinase phosphatase (MKP-1] expression is induced by low oxygen conditions found in solid tumor mi- croenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem 1999; 274: 12890-12897.
31. Zhang C, Kolb A, Mattern J, Gassier N, Wenger T, Herzer K et al. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer lett 2006; 242(1) 104-11.
32. Quante T, Ng YC, Ramsay EE, Henness S, Allen JC, Parmentier J et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 2008; 39(2): 208-217.
33. Fuerst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S et al. MAPK phosphatase-1 represents a noval anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 2007; 21(l):74-80.
34. Aeverli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. En dogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophases via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 2006; 580(3): 974-981.
35. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007;251:1-16.